Template:PDB Gallery/27

• 1ab2: THREE-DIMENSIONAL SOLUTION STRUCTURE OF THE SRC HOMOLOGY 2 DOMAIN OF C-ABL

  1ab2: THREE-DIMENSIONAL SOLUTION STRUCTURE OF THE SRC HOMOLOGY 2 DOMAIN OF C-ABL

• 1abo: CRYSTAL STRUCTURE OF THE COMPLEX OF THE ABL TYROSINE KINASE SH3 DOMAIN WITH 3BP-1 SYNTHETIC PEPTIDE

  1abo: CRYSTAL STRUCTURE OF THE COMPLEX OF THE ABL TYROSINE KINASE SH3 DOMAIN WITH 3BP-1 SYNTHETIC PEPTIDE

• 1abq: CRYSTAL STRUCTURE OF THE UNLIGANDED ABL TYROSINE KINASE SH3 DOMAIN

  1abq: CRYSTAL STRUCTURE OF THE UNLIGANDED ABL TYROSINE KINASE SH3 DOMAIN

• 1bbz: CRYSTAL STRUCTURE OF THE ABL-SH3 DOMAIN COMPLEXED WITH A DESIGNED HIGH-AFFINITY PEPTIDE LIGAND: IMPLICATIONS FOR SH3-LIGAND INTERACTIONS

  1bbz: CRYSTAL STRUCTURE OF THE ABL-SH3 DOMAIN COMPLEXED WITH A DESIGNED HIGH-AFFINITY PEPTIDE LIGAND: IMPLICATIONS FOR SH3-LIGAND INTERACTIONS

• 1fpu: CRYSTAL STRUCTURE OF ABL KINASE DOMAIN IN COMPLEX WITH A SMALL MOLECULE INHIBITOR

  1fpu: CRYSTAL STRUCTURE OF ABL KINASE DOMAIN IN COMPLEX WITH A SMALL MOLECULE INHIBITOR

• 1iep: CRYSTAL STRUCTURE OF THE C-ABL KINASE DOMAIN IN COMPLEX WITH STI-571.

  1iep: CRYSTAL STRUCTURE OF THE C-ABL KINASE DOMAIN IN COMPLEX WITH STI-571.

• 1ju5: Ternary complex of an Crk SH2 domain, Crk-derived phophopeptide, and Abl SH3 domain by NMR spectroscopy

  1ju5: Ternary complex of an Crk SH2 domain, Crk-derived phophopeptide, and Abl SH3 domain by NMR spectroscopy

• 1m52: Crystal Structure of the c-Abl Kinase domain in complex with PD173955

  1m52: Crystal Structure of the c-Abl Kinase domain in complex with PD173955

• 1opj: Structural basis for the auto-inhibition of c-Abl tyrosine kinase

  1opj: Structural basis for the auto-inhibition of c-Abl tyrosine kinase

• 2e2b: Crystal structure of the c-Abl kinase domain in complex with INNO-406

  2e2b: Crystal structure of the c-Abl kinase domain in complex with INNO-406

• 2f4j: Structure of the Kinase Domain of an Imatinib-Resistant Abl Mutant in Complex with the Aurora Kinase Inhibitor VX-680

  2f4j: Structure of the Kinase Domain of an Imatinib-Resistant Abl Mutant in Complex with the Aurora Kinase Inhibitor VX-680

• 2g1t: A Src-like Inactive Conformation in the Abl Tyrosine Kinase Domain

  2g1t: A Src-like Inactive Conformation in the Abl Tyrosine Kinase Domain

• 2g2f: A Src-like Inactive Conformation in the Abl Tyrosine Kinase Domain

  2g2f: A Src-like Inactive Conformation in the Abl Tyrosine Kinase Domain

• 2g2h: A Src-like Inactive Conformation in the Abl Tyrosine Kinase Domain

  2g2h: A Src-like Inactive Conformation in the Abl Tyrosine Kinase Domain

• 2g2i: A Src-like Inactive Conformation in the Abl Tyrosine Kinase Domain

  2g2i: A Src-like Inactive Conformation in the Abl Tyrosine Kinase Domain

• 2gqg: X-ray Crystal Structure of Dasatinib (BMS-354825) Bound to Activated ABL Kinase Domain

  2gqg: X-ray Crystal Structure of Dasatinib (BMS-354825) Bound to Activated ABL Kinase Domain

• 2hiw: Crystal Structure of Inactive Conformation Abl Kinase Catalytic Domain Complexed with Type II Inhibitor

  2hiw: Crystal Structure of Inactive Conformation Abl Kinase Catalytic Domain Complexed with Type II Inhibitor

• 2hyy: Human Abl kinase domain in complex with imatinib (STI571, Glivec)

  2hyy: Human Abl kinase domain in complex with imatinib (STI571, Glivec)

• 2hz0: Abl kinase domain in complex with NVP-AEG082

  2hz0: Abl kinase domain in complex with NVP-AEG082

• 2hz4: Abl kinase domain unligated and in complex with tetrahydrostaurosporine

  2hz4: Abl kinase domain unligated and in complex with tetrahydrostaurosporine

• 2hzi: Abl kinase domain in complex with PD180970

  2hzi: Abl kinase domain in complex with PD180970

• 2hzn: Abl kinase domain in complex with NVP-AFG210

  2hzn: Abl kinase domain in complex with NVP-AFG210